<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620828</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000233</org_study_id>
    <secondary_id>SPS# 139715</secondary_id>
    <nct_id>NCT00620828</nct_id>
  </id_info>
  <brief_title>The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty</brief_title>
  <official_title>The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty: A Double-Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use a new combination of anesthesia techniques in an attempt
      to minimize early pain after surgery and improve the patient's ability to participate more
      fully with physical therapy. Total knee replacement patients who participate will receive the
      standard anesthesia. This includes a spinal nerve block as well as a femoral nerve block. The
      study is looking at the added benefits of including an injection of numbing medication
      (Bupivicaine) to the back of the knee. This injection occurs during surgery. In order to
      compare the outcomes we will also have a group of patients who will receive a saline
      injection as opposed to the numbing medication. Patients are randomly assigned to a group.
      Outcomes are measured up until twenty-four hours following the surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Summary

      Purpose of Study This prospective, randomized, blinded controlled trial will be conducted to
      evaluate post-operative pain control and physical therapy outcomes in primary total knee
      arthroplasty (TKA) with the use of spinal analgesia and intra-operative posterior capsular
      injections of ropivicaine 0.5% in conjunction with a continuous femoral nerve catheter.

      We believe the results of this study will show an improvement in pain control and physical
      therapy outcomes compared to traditional methods of analgesia in post-op total knee
      arthroplasty. To the best of our knowledge, there are no studies in the literature using this
      combination of femoral nerve analgesia and posterior capsular injection.

      Certainly regional anesthesia methods such as femoral nerve blocks used alone or in
      conjunction with sciatic nerve blocks have improved patient pain outcome measures in total
      knee arthroplasty. Several studies have shown a beneficial effect of intra-articular
      analgesia after capsular closure. We believe our study design will combine the beneficial
      effects of the aforementioned methods, and ultimately improve patient pain, therapy effort,
      and safety through less narcotic use.

      Our goal is to share these results in a peer-reviewed journal, and at national orthopaedic or
      anesthesia meetings. The data collected will ideally improve care and safety in the
      post-operative total knee arthroplasty patient.

      Background and Significance Post-operative pain control in total knee arthroplasty is an area
      of great study in the orthopaedic surgery and anesthesia literature. The use of
      spinal/epidural alone or in combination with regional anesthesia is well studied in the
      recent literature. These techniques have significantly improved patient pain management,
      physical/occupational therapy outcomes, and shortened time to discharge.

      Additionally, intra-articular injection of local anesthetic after capsular closure has been
      studied recently. Several studies have demonstrated a beneficial effect of intra-articular
      local anesthetic on pain outcome measures (6, 8, 9, 10, 15). Although other studies have
      reported more equivocal results. The impact of capsular analgesia has on post-operative pain
      is intriguing. Decreased afferent pain perception by the capsular nerves from local
      anesthetic may improve outcomes, especially in sensory distributions where regional
      anesthesia is inadequate or not performed.

      Much study has centered on regional anesthesia, specifically the use of single shot or
      continuous femoral nerve blockade (4, 5, 11, 14, 16). Such studies have demonstrated a
      statistically significant decrease in total narcotic use, sedation scores, and visual analog
      pain scores. Femoral nerve blockade is now an accepted method of post-op pain control in the
      total knee arthroplasty patient.

      Further investigation has centered on the addition of sciatic nerve blockade to femoral nerve
      block (1-3, 7, 12, 13). Several studies demonstrate a further improvement in pain outcomes
      compared to isolated femoral nerve anesthesia. Sciatic nerve blocks can slow physical therapy
      efforts secondary to a dense motor blockade. Equivocal results have been reported in other
      studies due to this motor block, however, the sensory component appears to provide improved
      pain outcome measures.

      Femoral nerve blockade is a well-accepted modality for analgesia in total knee arthroplasty.
      However, femoral nerve block alone does not provide adequate anesthesia to the posterior
      aspect of the knee. We believe that intra-operative injection of ropivicaine 0.5% into the
      posterior capsule will provide analgesia analogous to the sensory component of a sciatic
      nerve block, while eliminating the limiting effects of the motor blockade. The combination of
      femoral nerve block and intra-operative posterior capsular injection will ideally yield
      improved pain management and physical therapy efforts above a baseline femoral nerve block.

      Design and procedures This is a prospective double-blinded, randomized trial consisting of
      two study groups: posterior capsular saline injection (control), and the experimental
      posterior capsular ropivicaine 0.5% injection group. All patients will receive spinal
      anesthesia and a continuous femoral nerve block. Each group will include 45 patients (n = 90
      patients).

      All patients will have an elective primary total knee arthroplasty performed. No revision or
      bilateral cases will be included. Exclusion criteria will include patients with a known
      allergy to ropivicaine or fentanyl, a known history of narcotic abuse or chronic pain, a
      known diagnosis of peripheral neuropathy or complex regional pain syndrome, or a significant
      impediment to physical therapy participation.

      Following the informed consent process, patients will receive a continuous femoral nerve
      block via catheter placed by experienced regional anesthesiologists at our institution. Each
      patient will also receive spinal anesthesia for intra-operative pain control. A standard
      midline skin incision with medial para-patellar arthrotomy will be performed followed by
      implantation of either a Next Gen (Zimmer/Warsaw, IN), or Natural Knee II (Zimmer, Warsaw,
      IN), or Posterior Femoral Component (PFC) Sigma (DePuy, Warsaw, IN) system. Prior to surgery,
      patients will be randomized to the saline or ropivicaine groups. Both groups will receive
      their respective injection prior to implantation of the components.

      The posterior capsule of the knee will be divided in to four quadrants, each receiving a
      saline or ropivicaine injection per randomization. Safety measures will include standard
      pre-injection aspiration to check for vascular blush and intra-operative Doppler ultrasound
      to identify vascular structures in the posterior knee. Additionally, the anesthesiologist
      will not be blinded, as he/she will be responsible for assuring the appropriate medication is
      used, and will be closely monitoring for cardiac arrhythmias in the unlikely event that an
      intravascular injection occurs. Post-operatively, a standard bulky dressing will be applied.
      All patients will be weight bearing as tolerated post-operative day 1. A fentanyl PCA will be
      initiated in the PACU, and will be continued until post-operative day 2. Dosing will be
      calculated based on lean body mass. Continuous femoral nerve blockade will continue until
      post-operative day 2 as well.

      Outcomes will include total PCA narcotic use, visual analog pain scale with a diagram to
      localize pain, and Ramsey sedation scores. This data will be collected at the following
      intervals: in the PACU, 4, 8, 12, and 24 hours post-operatively. We will also measure
      post-operative day 1 knee range of motion, total ambulation distance, and time to straight
      leg raise. A standard, Institutional Review Board (IRB) approved, data collection sheet will
      be utilized.

      We hypothesize that total post-operative narcotic use, visual analog pain scores, and Ramsey
      sedation scores will be significantly lower in the study group (posterior capsular
      ropivicaine 0.5% injection). Additionally, we anticipate the knee range of motion, total
      ambulation distance, and time to straight leg raise to be significantly improved as well.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric Pain Score</measure>
    <time_frame>Post-anesthesia care unit (PACU), 4 hours, 8 hours, 12 hours and 24 hours post-injection</time_frame>
    <description>Participants were asked to rate their pain on a scale of 0 to 10 at all time intervals up to 24 hours post-injection. Scores were organized into the following categories: 3 or less (mild pain), 4 to 6 (moderate pain), 7 or higher (severe pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Fentanyl Patient-Controlled Anesthesia (PCA) Narcotic Consumption</measure>
    <time_frame>4 hours to 24 hours post-op</time_frame>
    <description>The PCA total dose at the 4-hour, 8-hour, 12-hour and 24-hour post-operative time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Day 1 Physical Therapy Outcome - Ambulation Distance</measure>
    <time_frame>24 hours post-op</time_frame>
    <description>Ambulation distance walked by participants 24-hours post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Day 1 Physical Therapy Outcome- Knee Extension and Flexion</measure>
    <time_frame>24 hours post-op</time_frame>
    <description>Knee extension and knee flexion measured at 24-hours post-operatively for patient cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Day 1 Physical Therapy Outcome - Straight Leg Raise</measure>
    <time_frame>4 hours, 8 hours, 12 hours and 24 hours post-op</time_frame>
    <description>Straight Leg Raise (SLR): number of people that can perform a SLR at designated intervals</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Block Negative</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive intra-op saline injection per protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Block Positive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive intra-op Ropivicaine 0.5% injection per protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo saline injection</intervention_name>
    <description>20 cc of sterile, injectable saline</description>
    <arm_group_label>Block Negative</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivicaine 0.5%</intervention_name>
    <description>Ropivicaine</description>
    <arm_group_label>Block Positive</arm_group_label>
    <other_name>Hospiria</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is scheduled to undergo elective total knee replacement at Duke University
             Hospital.

          -  The subject has signed the written consent form.

        Exclusion Criteria:

          -  Known allergy to ropivacaine or hydromorphone.

          -  Known history of narcotic abuse or alcohol abuse.

          -  Known history of chronic pain.

          -  Known diagnosis of peripheral neuropathy or complex regional pain syndrome.

          -  Significant impediment to physical therapy participation.

          -  The surgery is a revision case.

          -  Patient is undergoing bilateral Total Knee Replacement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Bolognesi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Adult Reconstructive Surgery</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ben-David B, Schmalenberger K, Chelly JE. Analgesia after total knee arthroplasty: is continuous sciatic blockade needed in addition to continuous femoral blockade? Anesth Analg. 2004 Mar;98(3):747-9, table of contents.</citation>
    <PMID>14980931</PMID>
  </reference>
  <reference>
    <citation>Cook P, Stevens J, Gaudron C. Comparing the effects of femoral nerve block versus femoral and sciatic nerve block on pain and opiate consumption after total knee arthroplasty. J Arthroplasty. 2003 Aug;18(5):583-6.</citation>
    <PMID>12934209</PMID>
  </reference>
  <reference>
    <citation>Davies AF, Segar EP, Murdoch J, Wright DE, Wilson IH. Epidural infusion or combined femoral and sciatic nerve blocks as perioperative analgesia for knee arthroplasty. Br J Anaesth. 2004 Sep;93(3):368-74. Epub 2004 Jul 9.</citation>
    <PMID>15247111</PMID>
  </reference>
  <reference>
    <citation>Edwards ND, Wright EM. Continuous low-dose 3-in-1 nerve blockade for postoperative pain relief after total knee replacement. Anesth Analg. 1992 Aug;75(2):265-7.</citation>
    <PMID>1632541</PMID>
  </reference>
  <reference>
    <citation>Hirst GC, Lang SA, Dust WN, Cassidy JD, Yip RW. Femoral nerve block. Single injection versus continuous infusion for total knee arthroplasty. Reg Anesth. 1996 Jul-Aug;21(4):292-7.</citation>
    <PMID>8837185</PMID>
  </reference>
  <reference>
    <citation>Klasen JA, Opitz SA, Melzer C, Thiel A, Hempelmann G. Intraarticular, epidural, and intravenous analgesia after total knee arthroplasty. Acta Anaesthesiol Scand. 1999 Nov;43(10):1021-6.</citation>
    <PMID>10593465</PMID>
  </reference>
  <reference>
    <citation>Lau HP, Yip KM, Jiang CC. Regional nerve block for total knee arthroplasty. J Formos Med Assoc. 1998 Jun;97(6):428-30.</citation>
    <PMID>9650474</PMID>
  </reference>
  <reference>
    <citation>Lombardi AV Jr, Berend KR, Mallory TH, Dodds KL, Adams JB. Soft tissue and intra-articular injection of bupivacaine, epinephrine, and morphine has a beneficial effect after total knee arthroplasty. Clin Orthop Relat Res. 2004 Nov;(428):125-30.</citation>
    <PMID>15534532</PMID>
  </reference>
  <reference>
    <citation>Mauerhan DR, Campbell M, Miller JS, Mokris JG, Gregory A, Kiebzak GM. Intra-articular morphine and/or bupivacaine in the management of pain after total knee arthroplasty. J Arthroplasty. 1997 Aug;12(5):546-52.</citation>
    <PMID>9268795</PMID>
  </reference>
  <reference>
    <citation>Nechleba J, Rogers V, Cortina G, Cooney T. Continuous intra-articular infusion of bupivacaine for postoperative pain following total knee arthroplasty. J Knee Surg. 2005 Jul;18(3):197-202.</citation>
    <PMID>16152868</PMID>
  </reference>
  <reference>
    <citation>Niskanen RO, Strandberg N. Bedside femoral block performed on the first postoperative day after unilateral total knee arthroplasty: a randomized study of 49 patients. J Knee Surg. 2005 Jul;18(3):192-6.</citation>
    <PMID>16152867</PMID>
  </reference>
  <reference>
    <citation>Pham Dang C, Gautheron E, Guilley J, Fernandez M, Waast D, Volteau C, Nguyen JM, Pinaud M. The value of adding sciatic block to continuous femoral block for analgesia after total knee replacement. Reg Anesth Pain Med. 2005 Mar-Apr;30(2):128-33.</citation>
    <PMID>15765454</PMID>
  </reference>
  <reference>
    <citation>Szczukowski MJ Jr, Hines JA, Snell JA, Sisca TS. Femoral nerve block for total knee arthroplasty patients: a method to control postoperative pain. J Arthroplasty. 2004 Sep;19(6):720-5.</citation>
    <PMID>15343531</PMID>
  </reference>
  <reference>
    <citation>Tanaka N, Sakahashi H, Sato E, Hirose K, Ishii S. The efficacy of intra-articular analgesia after total knee arthroplasty in patients with rheumatoid arthritis and in patients with osteoarthritis. J Arthroplasty. 2001 Apr;16(3):306-11.</citation>
    <PMID>11307127</PMID>
  </reference>
  <reference>
    <citation>Wang H, Boctor B, Verner J. The effect of single-injection femoral nerve block on rehabilitation and length of hospital stay after total knee replacement. Reg Anesth Pain Med. 2002 Mar-Apr;27(2):139-44.</citation>
    <PMID>11915059</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2008</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <results_first_submitted>June 17, 2010</results_first_submitted>
  <results_first_submitted_qc>March 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2013</results_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>12 of the 79 subjects enrolled were screening failures, thus total number of subjects completing the study = 67. One patient had staged bilateral TKA so there are 66 total patients, but 67 injections given.</recruitment_details>
      <pre_assignment_details>12 of the 79 subjects enrolled were screening failures</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Subjects receive intra-op saline injection per protocol</description>
        </group>
        <group group_id="P2">
          <title>Block Group</title>
          <description>Subjects receive intra-op Ropivicaine 0.5% injection per protocol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number of Subjects Enrolled = 67</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Subjects receive intra-op saline injection per protocol</description>
        </group>
        <group group_id="B2">
          <title>Block Group</title>
          <description>Subjects receive intra-op Ropivicaine 0.5% injection per protocol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="2"/>
                    <measurement group_id="B2" value="66.9" spread="2"/>
                    <measurement group_id="B3" value="66.1" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lean Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="12.4"/>
                    <measurement group_id="B2" value="62.9" spread="11.1"/>
                    <measurement group_id="B3" value="61.4" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numeric Pain Score</title>
        <description>Participants were asked to rate their pain on a scale of 0 to 10 at all time intervals up to 24 hours post-injection. Scores were organized into the following categories: 3 or less (mild pain), 4 to 6 (moderate pain), 7 or higher (severe pain).</description>
        <time_frame>Post-anesthesia care unit (PACU), 4 hours, 8 hours, 12 hours and 24 hours post-injection</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Block Group</title>
            <description>Participants received a 20 mL posterior capsular injection of ropivicaine before cementation of final components. The posterior capsule of the knee was divided into 4 quadrants, each receiving a 5 mL injection of ropivicaine.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received a 20 mL posterior capsular injection of saline before cementation of final components. The posterior capsule of the knee was divided into 4 quadrants, each receiving a 5 mL injection of saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Numeric Pain Score</title>
          <description>Participants were asked to rate their pain on a scale of 0 to 10 at all time intervals up to 24 hours post-injection. Scores were organized into the following categories: 3 or less (mild pain), 4 to 6 (moderate pain), 7 or higher (severe pain).</description>
          <population>per protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PACU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="1.4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="1.6" spread="2.8" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.7"/>
                    <measurement group_id="O2" value="3.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.6"/>
                    <measurement group_id="O2" value="4.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.9"/>
                    <measurement group_id="O2" value="3.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.7"/>
                    <measurement group_id="O2" value="4.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patient cohort was inclusive of patient undergoing single TKA from June 2007 to July 2008. Effect size was calculated for the numeric pain rating scale at the immediate post-operative period, 4-hour, 8-hour , 12-hour, and 24-hour time periods as a means to assess post-operative pain control.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fentanyl Patient-Controlled Anesthesia (PCA) Narcotic Consumption</title>
        <description>The PCA total dose at the 4-hour, 8-hour, 12-hour and 24-hour post-operative time points.</description>
        <time_frame>4 hours to 24 hours post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Block Group</title>
            <description>Participants received a 20 mL posterior capsular injection of ropivicaine before cementation of final components. The posterior capsule of the knee was divided into 4 quadrants, each receiving a 5 mL injection of ropivicaine.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received a 20 mL posterior capsular injection of saline before cementation of final components. The posterior capsule of the knee was divided into 4 quadrants, each receiving a 5 mL injection of saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fentanyl Patient-Controlled Anesthesia (PCA) Narcotic Consumption</title>
          <description>The PCA total dose at the 4-hour, 8-hour, 12-hour and 24-hour post-operative time points.</description>
          <units>micrograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="38.1"/>
                    <measurement group_id="O2" value="43.7" spread="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" spread="103.3"/>
                    <measurement group_id="O2" value="126.6" spread="106.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.4" spread="175.4"/>
                    <measurement group_id="O2" value="205.6" spread="177.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.5" spread="424.4"/>
                    <measurement group_id="O2" value="292.2" spread="402.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Significant differences in Fentanyl PCA pump usage across study arms were assessed for the 4-8h,8-12h,and 12h-24h time frames.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Day 1 Physical Therapy Outcome - Ambulation Distance</title>
        <description>Ambulation distance walked by participants 24-hours post-operatively</description>
        <time_frame>24 hours post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Block Group</title>
            <description>Participants received a 20 mL posterior capsular injection of ropivicaine before cementation of final components. The posterior capsule of the knee was divided into 4 quadrants, each receiving a 5 mL injection of ropivicaine.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received a 20 mL posterior capsular injection of saline before cementation of final components. The posterior capsule of the knee was divided into 4 quadrants, each receiving a 5 mL injection of saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Day 1 Physical Therapy Outcome - Ambulation Distance</title>
          <description>Ambulation distance walked by participants 24-hours post-operatively</description>
          <units>Feet</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" spread="45.0"/>
                    <measurement group_id="O2" value="26.4" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis was performed on data collected 24-hours post-operatively for patient cohort.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Day 1 Physical Therapy Outcome- Knee Extension and Flexion</title>
        <description>Knee extension and knee flexion measured at 24-hours post-operatively for patient cohort</description>
        <time_frame>24 hours post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Block Group</title>
            <description>Participants received a 20 mL posterior capsular injection of ropivicaine before cementation of final components. The posterior capsule of the knee was divided into 4 quadrants, each receiving a 5 mL injection of ropivicaine.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received a 20 mL posterior capsular injection of saline before cementation of final components. The posterior capsule of the knee was divided into 4 quadrants, each receiving a 5 mL injection of saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Day 1 Physical Therapy Outcome- Knee Extension and Flexion</title>
          <description>Knee extension and knee flexion measured at 24-hours post-operatively for patient cohort</description>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Knee extension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="4.5"/>
                    <measurement group_id="O2" value="7.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Knee flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" spread="13.9"/>
                    <measurement group_id="O2" value="69.6" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Knee extension and knee flexion measured at 24-hours post-operatively for patient cohort.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Day 1 Physical Therapy Outcome - Straight Leg Raise</title>
        <description>Straight Leg Raise (SLR): number of people that can perform a SLR at designated intervals</description>
        <time_frame>4 hours, 8 hours, 12 hours and 24 hours post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Block Group</title>
            <description>Participants received a 20 mL posterior capsular injection of ropivicaine before cementation of final components. The posterior capsule of the knee was divided into 4 quadrants, each receiving a 5 mL injection of ropivicaine.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received a 20 mL posterior capsular injection of saline before cementation of final components. The posterior capsule of the knee was divided into 4 quadrants, each receiving a 5 mL injection of saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Day 1 Physical Therapy Outcome - Straight Leg Raise</title>
          <description>Straight Leg Raise (SLR): number of people that can perform a SLR at designated intervals</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SLR 4 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLR 8 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLR 12 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLR 24 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Straight leg raise data collected at 4-hours, 8-hours, 12-hours and 24-hours post-operatively for patient cohort.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Subjects receive intra-op saline injection per protocol</description>
        </group>
        <group group_id="E2">
          <title>Block Group</title>
          <description>Subjects receive intra-op Ropivicaine 0.5% injection per protocol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Bolognesi, MD</name_or_title>
      <organization>Duke UMC</organization>
      <phone>919-668-4732 ext 2</phone>
      <email>bolog002@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

